1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Blum J, Jones S, Buzdar A, LoRusso P, Kuter I, Vogel C, Osterwalder B, Burger H, Brown C, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. Journal Of Clinical Oncology 1999, 17: 485-93. PMID: 10080589, DOI: 10.1200/jco.1999.17.2.485.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerTreatment-related adverse eventsHand-foot syndromeBreast cancerAdverse eventsCommon treatment-related adverse eventsLarge multicenter phase II trialOnly treatment-related adverse eventMulticenter phase II studyMulticenter phase II trialComplete response durationPrior chemotherapeutic regimensPhase II studyPhase II trialMedian survival timeFavorable toxicity profileOverall response rateFluoropyrimidine carbamateMeasurable diseaseOral capecitabineAssessable diseaseII trialII studyMedian durationMetastatic diseasePhase II study of CI-958 in colorectal cancer
Shields A, Philip P, LoRusso P, Ferris A, Zalupski M. Phase II study of CI-958 in colorectal cancer. Cancer Chemotherapy And Pharmacology 1999, 43: 162-164. PMID: 9923823, DOI: 10.1007/s002800050878.Peer-Reviewed Original ResearchConceptsAdvanced colorectal cancerColorectal cancerCI-958Patient experienced febrile neutropeniaAcute febrile reactionExperienced febrile neutropeniaPhase II studyPhase II trialStart of treatmentFebrile neutropeniaII trialMetastatic settingII studyMajor toxicityMedian survivalMetastatic diseaseObjective responseFebrile reactionsPatientsCancerDoseTreatmentLeukopeniaNeutropeniaRegimen
1993
Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.
Visscher D, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman J. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Modern Pathology 1993, 6: 302-6. PMID: 8346178.Peer-Reviewed Original ResearchConceptsBreast carcinomaUrokinase-type plasminogen activatorShort-term recurrence-free survivalCathepsin DNode-positive patientsRecurrence-free survivalProteolytic enzyme expressionHeterogeneous staining patternFree survivalImmunohistologic evaluationMetastatic diseasePositive patientsInflammatory cellsNeoplastic epitheliumExtracellular matrix dissolutionSystematic metastasisClinical aggressivenessMost tumorsTumor componentsMetastatic capacityCryostat sectionsCarcinomaMonoclonal antibodiesStaining patternPlasminogen activator
1988
Chemotherapy for paranasal sinus carcinoma. A 10‐year experience at Wayne state university
Lorusso P, Tapazoglou E, Kish J, Ensley J, Cummings G, Kelly J, Al‐Sarraf M. Chemotherapy for paranasal sinus carcinoma. A 10‐year experience at Wayne state university. Cancer 1988, 62: 1-5. PMID: 2454717, DOI: 10.1002/1097-0142(19880701)62:1<1::aid-cncr2820620102>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsUntreated patientsRecurrent diseaseMedian survivalRole of chemotherapyMajority of patientsManagement of patientsParanasal sinus carcinomaSquamous cell carcinomaOverall response rateResponse 3 monthsAdjuvant chemotherapyEvaluable patientsMeasurable diseaseParanasal cancerPatients 88Predominant toxicityCNS involvementRenal impairmentAdvanced patientsMetastatic diseaseMale patientsRecurrent patientsSinus carcinomaFemale patientsCell carcinoma